C3 and age-related macular degeneration: Therapeutic compounds like Eculizumab (anti-C5 mAb) or Compstatin (anti-C3 peptide) target the central serine-proteases of all three complement pathways and are tested in clinical studies for aHUS as well as AMD, respectively [59], [60].